VERTEX PHARMACEUTICALS INC / MA
VRTXAPI behind this page
VRTX Q1 2026 request
Playground key active
/api/financials?ticker=VRTX&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 2,986.9 | 2,770.2 | +7.8% |
Show Product Lines breakouts |
|||
| ALYFTREK | 424.4 | 53.9 | +687.4% |
| CASGEVY | 42.9 | 14.2 | +202.1% |
| JOURNAVX | 29 | 1.3 | +2130.8% |
| Manufactured Product Other | 135.9 | 155.3 | -12.5% |
| Product | 2,986.9 | 2,760.2 | +8.2% |
| Product · Accumulated Translation Adjustment | -25.5 | 24.1 | -205.8% |
| Total CF product revenues, net | 2,915 | 2,744.7 | +6.2% |
| TRIKAFTA/KAFTRIO | 2,354.7 | 2,535.5 | -7.1% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 2,986.9 | 2,770.2 | +7.8% |
Show Geography breakouts |
|||
| Europe | 950 | 826.6 | +14.9% |
| Non Us | 1,211 | 1,106.7 | +9.4% |
| Other | 261 | 280.1 | -6.8% |
| US | 1,775.9 | 1,663.5 | +6.8% |
| Cost of Revenue | 392.8 | 363 | +8.2% |
Show Product Lines breakouts |
|||
| Product · Pharmaceuticals | 160.2 | 130.6 | +22.7% |
| Royalty · Pharmaceuticals | 232.6 | 232.4 | +0.1% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 23.1 | 36.2 | -36.2% |
| Research And Development Expense Excluding Acquired In Process Cost | 961.6 | 979.7 | -1.8% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 16.1 | 16 | +0.6% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 0.5 | 19.8 | -97.5% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 0.5 | 19.8 | -97.5% |
| Selling, General & Administrative | 493.7 | 396.4 | +24.5% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 0.2 | 2.2 | -90.9% |
| Total Costs & Expenses | 1,848.8 | 2,140.1 | -13.6% |
| Operating Income | 1,138.1 | 630.1 | +80.6% |
| Investment Income Net | 114.8 | 117.9 | -2.6% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 114.8 | 117.9 | -2.6% |
| Other Non-Operating Income (Expense) (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Foreign Exchange Forward | 2.9 | -1.2 | +341.7% |
| Income Before Taxes | 1,252.9 | 730.4 | +71.5% |
| Income Tax Expense (Benefit) | 221.5 | 84.1 | +163.4% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 221.5 | 84.1 | +163.4% |
| Net Income | 1,031.4 | 646.3 | +59.6% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 1,031.4 | 646.3 | +59.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,031.4 | 646.3 | +59.6% |
| EPS (Basic) | 4.06 | 2.52 | +61.1% |
| EPS (Diluted) | 4.02 | 2.49 | +61.4% |
| Wtd Avg Shares (Basic) | 254.1 | 256.9 | -1.1% |
| Wtd Avg Shares (Diluted) | 256.3 | 259.5 | -1.2% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 180.1 | 155.3 | +16.0% |
| Comprehensive Income | 1,072.1 | 586.6 | +82.8% |
| Other Comprehensive Income | 40.7 | -59.7 | +168.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 84.9 | -90.3 | +194.0% |
| Accumulated Net Unrealized Investment Gain Loss | -31.2 | 16.5 | -289.1% |
| Accumulated Other Comprehensive Income | 40.7 | -59.7 | +168.2% |
| Accumulated Translation Adjustment | -13 | 14.1 | -192.2% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,492.9 | 4,674.7 | +17.5% |
| Marketable Securities (Current) | 1,753.8 | 1,526.5 | +14.9% |
| Accounts Receivable | 1,996.1 | 1,805.1 | +10.6% |
| Inventory | 1,766.7 | 1,359.7 | +29.9% |
| Prepaid Expenses & Other Current Assets | 720.8 | 642.8 | +12.1% |
| Total Current Assets | 11,730.3 | 10,008.8 | +17.2% |
| Non-Current Assets | |||
| Goodwill | 1,088 | 1,088 | 0.0% |
| Deferred Tax Assets | 2,947.8 | 2,544.3 | +15.9% |
| Operating Lease Right-of-Use Assets | 1,685.1 | — | — |
Show Geography breakouts |
|||
| NH | 95.8 | — | — |
| Marketable Securities (Non-Current) | 5,749.9 | 5,156.5 | +11.5% |
| Other Non-Current Assets | 1,256.4 | 1,007.3 | +24.7% |
| Total Assets | 26,484.4 | 22,880.5 | +15.8% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Employment Contracts | 3 | 5.5 | -45.5% |
| Marketing Related Intangible Assets | 190.9 | 211.1 | -9.6% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,608.4 | 1,295.9 | +24.1% |
| Intangible Assets Net Excluding Goodwill | 418.5 | 441.2 | -5.1% |
| Current Liabilities | |||
| Accounts Payable | 489.3 | 445 | +10.0% |
| Accrued Liabilities | 2,984.2 | 2,951.8 | +1.1% |
| Other Liabilities Current | 407.1 | 386.4 | +5.4% |
| Total Current Liabilities | 3,880.6 | 3,783.2 | +2.6% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 1,986.5 | — | — |
Show Geography breakouts |
|||
| NH | 95.8 | — | — |
| Other Non-Current Liabilities | 1,255.4 | 951.9 | +31.9% |
| Total Liabilities | 7,122.5 | 6,384.2 | +11.6% |
| Stockholders' Equity | |||
| Common Stock | 2.5 | 2.6 | -3.8% |
| Additional Paid In Capital Common Stock | 4,743.2 | 6,172.5 | -23.2% |
| Accumulated Other Comprehensive Income | 24.8 | 68.1 | -63.6% |
| Retained Earnings | 14,591.4 | 10,253.1 | +42.3% |
| Total Stockholders' Equity | 19,361.9 | 16,496.3 | +17.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -2.2 | 20.7 | -110.6% |
| Accumulated Net Unrealized Investment Gain Loss | 2.8 | 23.6 | -88.1% |
| Accumulated Other Comprehensive Income | 24.8 | 68.1 | -63.6% |
| Accumulated Translation Adjustment | 24.2 | 23.8 | +1.7% |
| Additional Paid In Capital | 4,743.2 | 6,172.5 | -23.2% |
| Common Stock | 2.5 | 2.6 | -3.8% |
| Retained Earnings | 14,591.4 | 10,253.1 | +42.3% |
| Total Liabilities & Equity | 26,484.4 | 22,880.5 | +15.8% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 166.4 | 166.1 | +0.2% |
| Depreciation & Amortization | 55.9 | 48.4 | +15.5% |
| Increase Decrease In Other Deferred Liability | -65.3 | -191.6 | +65.9% |
| Other Non-Cash Items | -5 | 39.2 | -112.8% |
| Change in Accounts Receivable | 39.8 | -169.6 | +123.5% |
| Change in Inventory | -97.7 | -167.1 | +41.5% |
| Change in Prepaid & Other Assets | 173.4 | -28.1 | +717.1% |
| Change in Accounts Payable | 35.6 | 26.2 | +35.9% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 70.5 | 48.1 | +46.6% |
| Increase Decrease In Other Operating Liabilities | 23.1 | 22 | +5.0% |
| Net Cash from Operations | 1,428.1 | 818.9 | +74.4% |
| Investing Activities | |||
| Purchases of Investments | -2,507.6 | -1,647.4 | -52.2% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 2,209.1 | 1,637.6 | +34.9% |
| Capital Expenditures | -133.4 | -40.7 | -227.8% |
| Net Cash from Investing | -431.9 | -55.8 | -674.0% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 27 | 16.7 | +61.7% |
| Share Repurchases | -336.9 | -426.1 | +20.9% |
| Tax Withholding for Share Compensation | -228.5 | -270.5 | +15.5% |
| Proceeds From Payments For Other Financing Activities | -0.4 | -0.5 | +20.0% |
| Net Cash from Financing | -538.8 | -680.4 | +20.8% |
| Supplemental | |||
| Income Taxes Paid | 82.3 | 184.4 | -55.4% |
| Interest Paid | 3.2 | 2.7 | +18.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -40.3 | 30.5 | -232.1% |
| Net Change in Cash | 417.1 | 113.2 | +268.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5,504.9 | 4,685.4 | +17.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.